J Scott Miners

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1722129/publications.pdf

Version: 2024-02-01

45 papers	2,710 citations	172457 29 h-index	223800 46 g-index
47 all docs	47 docs citations	47 times ranked	4157 citing authors

#	Article	IF	Citations
1	Pathological changes within the cerebral vasculature in Alzheimerâ€™s disease: New perspectives. Brain Pathology, 2022, 32, e13061.	4.1	28
2	Dysregulation of ACE-1 in Normal Aging and the Early Stages of Alzheimerâ€™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 1775-1783.	3.6	10
3	Mediators of cerebral hypoperfusion and bloodâ€brain barrier leakiness in Alzheimerâ€™s disease, vascular dementia and mixed dementia. Brain Pathology, 2021, 31, e12935.	4.1	38
4	Systemic infection exacerbates cerebrovascular dysfunction in Alzheimerâ€™s disease. Brain, 2021, 144, 1869-1883.	7.6	32
5	Pericyte Contractile Responses to Endothelin-1 and AÎ² Peptides: Assessment by Electrical Impedance Assay. Frontiers in Cellular Neuroscience, 2021, 15, 723953.	3.7	10
6	ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimerâ€™s disease. Acta Neuropathologica, 2020, 139, 485-502.	7.7	101
7	Cognitive impact of COVID-19: looking beyond the short term. Alzheimer's Research and Therapy, 2020, 12, 170.	6.2	149
8	Exploring the putative role of kallikreinâ€6, calpainâ€1 and cathepsinâ€D in the proteolytic degradation of Î±â€synuclein in multiple system atrophy. Neuropathology and Applied Neurobiology, 2019, 45, 347-360.	3.2	16
9	Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 72, 525-535.	2.6	16
10	CSF evidence of pericyte damage in Alzheimerâ€™s disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Alzheimer's Research and Therapy, 2019, 11, 81.	6.2	72
11	Divergence in the activity of the N- and C- catalytic domains of ACE1 - implications for the role of the renin-angiotensin system in Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2019, 7, 57.	5.2	5
12	Differing associations between AÎ² accumulation, hypoperfusion, bloodâ€“brain barrier dysfunction and loss of PDGFRB pericyte marker in the precuneus and parietal white matter in Alzheimer's disease. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 103-115.	4.3	147
13	Clusterin levels are increased in <scp>A</scp>lzheimer's disease and influence the regional distribution of AÎ². Brain Pathology, 2017, 27, 305-313.	4.1	59
14	Endothelinâ€converting enzymes degrade Î±â€synuclein and are reduced in dementia with Lewy bodies. Journal of Neurochemistry, 2017, 141, 275-286.	3.9	7
15	Angiotensin-III is Increased in Alzheimerâ€™s Disease in Association with Amyloid-Î² and Tau Pathology. Journal of Alzheimer's Disease, 2017, 58, 203-214.	2.6	37
16	Small vessel disease, neurovascular regulation and cognitive impairment: post-mortem studies reveal a complex relationship, still poorly understood. Clinical Science, 2017, 131, 1579-1589.	4.3	19
17	Cerebral Hypoperfusion and the Energy Deficit in <scp>A</scp>lzheimer's Disease. Brain Pathology, 2016, 26, 607-617.	4.1	57
18	Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-Î² (AÎ²) Plaque Load and AÎ²-Synthesizing and AÎ²-Degrading Enzymes in Frontal Cortex. Journal of Alzheimer's Disease, 2016, 50, 1191-1203.	2.6	46

#	Article	IF	Citations
19	Angiotensin-converting enzyme 2 is reduced in Alzheimerâ€™s disease in association with increasing amyloid-Î² and tau pathology. Alzheimer's Research and Therapy, 2016, 8, 50.	6.2	159
20	Cerebrovascular disease in ageing and Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 131, 645-658.	7.7	218
21	Pathophysiology of Hypoperfusion of the Precuneus in Early <scp>A</scp>lzheimer's Disease. Brain Pathology, 2016, 26, 533-541.	4.1	81
22	Investigation of <scp>A</scp>Î² phosphorylated at serine 8 (p<scp>A</scp>Î²) in <scp>A</scp>lzheimer's disease, dementia with <scp>L</scp>ewy bodies and vascular dementia. Neuropathology and Applied Neurobiology, 2015, 41, 428-444.	3.2	16
23	White Matter Hypoperfusion and Damage in Dementia: Postâ€Mortem Assessment. Brain Pathology, 2015, 25, 99-107.	4.1	30
24	AÃŽÂ² degradation or cerebral perfusion? Divergent effects of multifunctional enzymes. Frontiers in Aging Neuroscience, 2014, 6, 238.	3.4	39
25	Accumulation of Î±-synuclein in dementia with Lewy bodies is associated with decline in the Î±-synuclein-degrading enzymes kallikrein-6 and calpain-1. Acta Neuropathologica Communications, 2014, 2, 164.	5.2	13
26	Evaluating the relationship between amyloid-Î² and Î±-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinsonâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 77.	6.2	74
27	Prion Protein Is Decreased in Alzheimer's Brain and Inversely Correlates with BACE1 Activity, Amyloid-Î² Levels and Braak Stage. PLoS ONE, 2013, 8, e59554.	2.5	35
28	BIN1 Is Decreased in Sporadic but Not Familial Alzheimerâ€™s Disease or in Aging. PLoS ONE, 2013, 8, e78806.	2.5	65
29	Convection-Enhanced Delivery of Neprilysin: A Novel Amyloid-Î²-Degrading Therapeutic Strategy. Journal of Alzheimer's Disease, 2012, 32, 43-56.	2.6	39
30	AÎ²-Degrading Enzymes: Potential for Treatment of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2011, 70, 944-959.	1.7	228
31	Oxidative Balance in Alzheimer's Disease: Relationship to APOE, Braak Tangle Stage, and the Concentrations of Soluble and Insoluble Amyloid-Î². Journal of Alzheimer's Disease, 2011, 22, 1363-1373.	2.6	41
32	Accumulation of Insoluble Amyloid-Î² in Down's Syndrome is Associated with Increased BACE-1 and Neprilysin Activities. Journal of Alzheimer's Disease, 2011, 23, 101-108.	2.6	30
33	Neprilysin Protects against Cerebral Amyloid Angiopathy and AÎ²â€Induced Degeneration of Cerebrovascular Smooth Muscle Cells. Brain Pathology, 2011, 21, 594-605.	4.1	38
34	Angiotensin II-inhibiting drugs have no effect on intraneuronal AÎ² or oligomeric AÎ² levels in a triple transgenic mouse model of Alzheimer's disease. American Journal of Translational Research (discontinued), 2011, 3, 197-208.	0.0	22
35	Oligomeric AÎ² in Alzheimer's Disease: Relationship to Plaque and Tangle Pathology, APOE Genotype and Cerebral Amyloid Angiopathy. Brain Pathology, 2010, 20, 468-480.	4.1	57
36	Higher Soluble Amyloid Î² Concentration in Frontal Cortex of Young Adults than in Normal Elderly or Alzheimer's Disease. Brain Pathology, 2010, 20, 787-793.	4.1	41

#	Article	IF	Citations
37	Changes with Age in the Activities of Î²â€Secretase and the AÎ²â€Degrading Enzymes Neprilysin, Insulinâ€Degrading Enzyme and Angiotensinâ€Converting Enzyme. Brain Pathology, 2010, 20, 794-802.	4.1	82
38	ACE variants and association with brain AÎ² levels in Alzheimer's disease. American Journal of Translational Research (discontinued), 2010, 3, 73-80.	0.0	32
39	Neprilysin and Insulin-Degrading Enzyme Levels Are Increased in Alzheimer Disease in Relation to Disease Severity. Journal of Neuropathology and Experimental Neurology, 2009, 68, 902-914.	1.7	95
40	Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. Journal of Neuroscience Methods, 2008, 167, 229-236.	2.5	41
41	Immunocapture-based fluorometric assay for the measurement of insulin-degrading enzyme activity in brain tissue homogenates. Journal of Neuroscience Methods, 2008, 169, 177-181.	2.5	26
42	Angiotensinâ€converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACEâ€1 to cerebral amyloid angiopathy. Neuropathology and Applied Neurobiology, 2008, 34, 181-193.	3.2	136
43	Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2007, 33, 317-327.	3.2	29
44	Decreased Expression and Activity of Neprilysin in Alzheimer Disease Are Associated With Cerebral Amyloid Angiopathy. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1012-1021.	1.7	132
45	Inhibition of Coxsackie B Virus Infection by Soluble Forms of Its Receptors: Binding Affinities, Altered Particle Formation, and Competition with Cellular Receptors. Journal of Virology, 2005, 79, 12016-12024.	3.4	61